Loading patent…
AssigneesIcahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America as represented by the Secretary of Agriculture
InventorsPeter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
Estimating the term…
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
A genetically engineered attenuated swine influenza virus having an impaired interferon antagonist phenotype, wherein said virus comprises a swine influenza virus A/Swine/Texas/4199-2/98 NS1 gene with a mutation resulting in an NS1 protein with a deletion of all of the amino acid residues of NS1 protein except amino acid residues 1-126, wherein the amino terminal amino acid is number 1 and the mutation in the NS 1 gene confers an impaired interferon antagonist phenotype.
Dependencies are inferred from the claim text.